Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 681 to 690 of 1090 total matches.
Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
received tebentafusp.
DRUG INTERACTIONS – Elevations in some
proinflammatory cytokines may suppress ...
The FDA has approved tebentafusp-tebn (Kimmtrak –
Immunocore), a first-in-class bispecific gp100
peptide-HLA-directed CD3 T-cell engager, for
treatment of HLA-A*02:01-positive unresectable or
metastatic uveal melanoma in adults.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e107-8 doi:10.58347/tml.2024.1705f | Show Introduction Hide Introduction
Daridorexant (Quviviq) for Insomnia
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
, and
hallucinations have occurred.
▶ Drug Interactions: Use with strong CYP3A4 inhibitors or strong
or moderate ...
The FDA has approved daridorexant (Quviviq –
Idorsia), an orexin receptor antagonist, for treatment
of sleep-onset and/or sleep-maintenance insomnia
in adults. Daridorexant is the third orexin receptor
antagonist to be approved for this indication;
suvorexant (Belsomra) and lemborexant (Dayvigo)
were approved earlier.
A New Testosterone Gel (Fortesta) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011 (Issue 1362)
,
particularly in older men.
DRUG INTERACTIONS — Increased monitoring of
INR or prothrombin time is recommended ...
The FDA has approved Fortesta (Endo), a topical gel,
for testosterone replacement therapy in adult males
with hypogonadism. It is classified as a Schedule III
controlled substance. Table 1 lists some available
testosterone products, including 2 other gels.
Erythropoietin Safety Concerns
The Medical Letter on Drugs and Therapeutics • May 07, 2007 (Issue 1260)
EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D., University of Washington
ADVISORY BOARD ...
The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood cell transfusions. Based on the results of recent clinical trials indicating an increased risk of serious adverse events and death associated with ESAs, particularly when used to achieve a hemoglobin concentration ≥12 g/dL, the FDA has revised the prescribing information for these drugs to include a black box warning.
An Oral Cholera Vaccine for Travelers (Vaxchora)
The Medical Letter on Drugs and Therapeutics • Aug 29, 2016 (Issue 1502)
during vaginal delivery.
DRUG INTERACTIONS — Antibiotics may be active
against the vaccine strain ...
The FDA has approved Vaxchora (PaxVax), a single-dose,
oral, live-attenuated cholera vaccine, to protect
against disease caused by Vibrio cholerae serogroup
O1 in adults 18-64 years old traveling to cholera-affected
areas. Vaxchora is the only cholera vaccine
available in the US. A whole-cell killed injectable
vaccine was previously approved, but is no longer
available in the US.
A New Sunscreen Agent
The Medical Letter on Drugs and Therapeutics • May 20, 2007 (Issue 1261)
University
EDITOR, DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS ...
Ecamsule (terephthalylidene dicamphor sulfonic acid), the first new sunscreen agent to be approved by the FDA in 18 years, is now available in the US in a moisturizer called Anthelios SX. Ecamsule has been used in Canada and Europe for more than 10 years.
Viloxazine ER (Qelbree) for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
or hepatic
impairment or for drug or genome interactions may be required.
2. Approximate WAC for 30 days ...
The FDA has approved viloxazine extended-release
capsules (Qelbree – Supernus) for treatment of
attention-deficit/hyperactivity disorder (ADHD) in
children 6-17 years old. Viloxazine is the second
selective norepinephrine reuptake inhibitor to be
approved in the US for treatment of ADHD; atomoxetine
(Strattera, and generics) was approved in 2002.
Two New Fluoroquinolones
The Medical Letter on Drugs and Therapeutics • Jun 12, 1992 (Issue 872)
or for pregnant or nursing women (JS Wolfson and DC Hooper, Am
J Med, 91 suppl 6A:153S, 1991).
DRUG INTERACTIONS ...
Temafloxacin (Omniflox - Abbott) and lomefloxacin (Maxaquin - Searle) are the latest fluoroquinolone antimicrobial agents to be approved by the US Food and Drug Administration (FDA) for oral treatment of various infections. Previously marketed include norfloxacin (Noroxin - Medical Letter, 29:25, 1987), ciprofloxacin (Cipro - Medical Letter, 30:11, 1988), and ofloxacin (Floxin - Medical Letter, 33:71, 1991). Norfloxacin is marketed only for treatment of urinary tract infections, and lomefloxacin only for treatment of urinary tract infections and bronchitis known to be caused by...
Gabapentin (Neurontin) for Chronic Pain
The Medical Letter on Drugs and Therapeutics • Apr 12, 2004 (Issue 1180)
.
DRUG INTERACTIONS — Gabapentin does not induce or inhibit hepatic microsomal
enzymes. Antacids ...
Gabapentin (Neurontin - Pfizer), which has been available in the US since 1994, is approved by the FDA only for treatment of partial epilepsy and postherpetic neuralgia, but is widely used off-label for a number of other indications, especially neuropathic pain syndromes. According to one report, among Medicaid recipients in Florida receiving gabapentin, 71% of prescriptions were for chronic pain and 8% for seizures and neuralgia ("The Pink Sheet" February 2, 2004; 66:30).
Osmolex ER - Another Extended-Release Amantadine for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Sep 10, 2018 (Issue 1555)
, confusion,
neuroleptic malignant syndrome, and acute delirium.
DRUG INTERACTIONS — Coadministration ...
The FDA has approved an extended-release tablet
formulation of amantadine (Osmolex ER – Vertical/Osmotica) for once-daily treatment of Parkinson's
disease (PD) and drug-induced extrapyramidal
symptoms (EPS) in adults. An extended-release
capsule formulation of amantadine (Gocovri) was
approved in 2017 for treatment of levodopa-induced
dyskinesia in patients with PD.